From Concept to Clinical-Ready: How MEEVA Shaped Vyrithal with VR Health Champions

Over the past year, MEEVA has transformed an early-stage idea into a clearly defined VR healthcare product with real-world deployment in sight. Through VR Health Champions, the team not only refined its technology but also laid solid foundations for regulatory readiness and future market entry.

Turning an idea into a product

Looking back at the first year within VR Health Champions, MEEVA points to one achievement as particularly decisive: the development of Vyrithal, its new single-player VR solution designed for autistic children.

What started as a concept evolved, within the project framework, into a fully scoped product with a complete design freeze. This process went far beyond technical iteration. It involved rethinking the system architecture, refining the user experience, and sharpening the product’s positioning to ensure scalability and suitability for real-world clinical and educational settings.

“Within the VR Health Champions framework, Vyrithal evolved from an initial concept into a clearly defined product, reaching a full design freeze. Having the space, guidance, and structured roadmap provided by the project was key to turning an idea into a concrete, well-scoped product,” says Marco Mosetti, MEEVA Srl Società Benefit.

This milestone marked a turning point for MEEVA, allowing the team to move forward with clarity and confidence in both development and strategy.

Navigating regulatory complexity

One of the most demanding aspects of the year was building a solid regulatory pathway. MEEVA has been working towards positioning Vyrithal as a Class I medical device, a goal that requires careful alignment between clinical ambition, technical design, and regulatory constraints.

The process proved complex and resource intensive. Defining the intended use, making informed design choices, and ensuring coherence across all product layers demanded continuous effort and expertise. Yet this challenge also strengthened the foundations of the solution.

“Achieving this goal is far from trivial. The work is complex and demanding, but it is also a crucial step to ensure credibility, safety, and long-term sustainability of the solution,” Mosetti explains.

Rather than slowing progress, the regulatory focus helped the team make more deliberate decisions and reinforced the product’s long-term viability.

Collaboration driven by results

Throughout the year, MEEVA worked closely with Inova+, describing the collaboration as pragmatic and strongly results-oriented. The support received focused on translating strategic concepts into tangible product-level actions.

One concrete outcome of this cooperation is the ongoing design of an AI-based system that will integrate intelligent agents directly into Vyrithal. These agents are being developed to reflect the real interaction patterns and needs of autistic boys and girls, ensuring coherence with MEEVA’s clinical and user-centred approach.

“This work gives MEEVA access to state-of-the-art technology while remaining aligned with safety, usability, and regulatory constraints,” says Mosetti.

The team sees this evolution as a key differentiator that will strengthen both the product itself and its positioning in the digital health and VR therapy market.

Looking ahead to year two

As VR Health Champions enters its second year, MEEVA’s priorities are clear. On one hand, the focus will shift towards the market, with strong emphasis on structuring a robust business plan and preparing for the next growth phase together with new and existing partners.

On the other hand, regulatory work will continue, with the aim of advancing certification and moving towards CE marking. Keeping market strategy and regulatory compliance aligned will be essential to ensure a credible and smooth path to adoption.

“This is where, for us, the real fun begins — turning a strong product into a sustainable business,” Mosetti adds.

What makes VR Health Champions different

Asked what distinguishes VR Health Champions from other innovation initiatives, MEEVA highlights one defining feature: alignment. The project’s objectives closely match the real needs of an SME developing a healthcare solution, from product development and regulatory readiness to market positioning and sustainability.

“If we had to describe VR Health Champions in one word, it would be pragmatic — because it supports innovation while staying firmly grounded in what it actually takes to bring a VR healthcare solution to market,” Mosetti concludes.